ivci:bordeaux_2025

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
ivci:bordeaux_2025 [2025/05/30 08:28] – [To Be Added] fkaagivci:bordeaux_2025 [2025/05/30 08:47] (current) – fkaag
Line 19: Line 19:
 ====== Bordeaux 2025 Meeting Summary ====== ====== Bordeaux 2025 Meeting Summary ======
  
-**Date:** May 9, 2025   +**Date:** May 9, 2025  \\ 
-**Location:** Radisson Blu Hotel, Bordeaux, France   +**Location:** Radisson Blu Hotel, Bordeaux, France  \\ 
-**Event:** International Summit on Vaccine Coding & Standards  +**Event:** International Summit on Vaccine Coding & Standards  \\
 **Hosted by:** International Vaccine Codes Initiative (IVCI) **Hosted by:** International Vaccine Codes Initiative (IVCI)
  
Line 43: Line 43:
 ===== Session Summaries ===== ===== Session Summaries =====
  
-=== Foundations & Global Perspectives ===+  FOUNDATIONS AND GLOBAL PERSPECTIVES
  
 ==== NUVA: What It Is and Why It Matters ==== ==== NUVA: What It Is and Why It Matters ====
Line 52: Line 52:
  
  
-=== Key Takeaways ===+=== Key Points ===
  
 **Origins and Evolution**   **Origins and Evolution**  
Line 100: Line 100:
  
 ==== How NUVA Uses Valences to Standardize Vaccine Codes ==== ==== How NUVA Uses Valences to Standardize Vaccine Codes ====
-//Speaker: Jean-Louis Koeck//+//Speaker: Jean-Louis Koeck (Syadem)//
  
 This presentation provided critical clinical context for understanding the valence model at the heart of NUVA. This presentation provided critical clinical context for understanding the valence model at the heart of NUVA.
  
-== Key Takeaways ==+=== Key Points ===
  
   * **Core Definitions**: Jean-Louis began by clearly defining "Vaccine" and "Antigen"—foundational concepts in immunology shared globally. While basic, these helped establish common ground for a diverse audience.   * **Core Definitions**: Jean-Louis began by clearly defining "Vaccine" and "Antigen"—foundational concepts in immunology shared globally. While basic, these helped establish common ground for a diverse audience.
Line 117: Line 117:
     - Vaccine prescription using valence labels rather than commercial product names     - Vaccine prescription using valence labels rather than commercial product names
  
-== In Summary ==+=== In Summary ===
 Valences offer a **common clinical language** to assess protection, regardless of which product or national code system is used. This session made clear that valences are the **core bridge** between vaccination data and actionable immunization guidance. Valences offer a **common clinical language** to assess protection, regardless of which product or national code system is used. This session made clear that valences are the **core bridge** between vaccination data and actionable immunization guidance.
  
Line 154: Line 154:
  
  
-=== Real-World Use Cases – Global & European Union ===+  REAL-WORD USE CASES - GLOBAL AND EUROPEAN UNION
  
 ==== EU Strategy for Cross-Border Vaccination Records ==== ==== EU Strategy for Cross-Border Vaccination Records ====
 //Speaker: Georgios Margetidis, Health and Digital European Agency (HaDEA)// //Speaker: Georgios Margetidis, Health and Digital European Agency (HaDEA)//
  
 +=== Key points ===
 Georgios presented the frame for the European Commission (EC) actions in the field of digital health. Georgios presented the frame for the European Commission (EC) actions in the field of digital health.
  
Line 166: Line 167:
  
 An harmonized approach for recording administered vaccines would be a significant contribution to this objective. Patient summaries, including vaccination history, should be exchangeable across all Member States by March 2029. An harmonized approach for recording administered vaccines would be a significant contribution to this objective. Patient summaries, including vaccination history, should be exchangeable across all Member States by March 2029.
 +=== In summary ===
 +The EHDS regulation allows the EC to become prescriptive on interoperability.
  
 ==== View from the Industry (ePIL & NUVA Integration) ==== ==== View from the Industry (ePIL & NUVA Integration) ====
Line 223: Line 226:
  
  
-=== Real-World Use Cases – Countries ===+  REAL-WORK USE CASES - COUNTRIES
  
 ==== Luxembourg Experience ==== ==== Luxembourg Experience ====
-//Speaker: Maud Delporte* (Agence eSanté Luxembourg)//+//Speaker: Maud Delporte (Agence eSanté Luxembourg)//
  
 Maud Delporte shared the ongoing efforts in Luxembourg to digitize and centralize vaccine histories through the **Carnet de Vaccination Électronique (CVE)**—a national immunization registry built with NUVA at its core. Maud Delporte shared the ongoing efforts in Luxembourg to digitize and centralize vaccine histories through the **Carnet de Vaccination Électronique (CVE)**—a national immunization registry built with NUVA at its core.
Line 382: Line 385:
  
  
- +  IMPLEMENTING NUVA FOR INTEROPERABILITY
-=== Implementing NUVA for Interoperability ===+
  
 ==== Mapping Across Code Systems ==== ==== Mapping Across Code Systems ====
Line 426: Line 428:
  
 ==== Metrics on Code Systems ==== ==== Metrics on Code Systems ====
-*Speaker: François Kaag (IVCI/SYADEM)*+//Speaker: François Kaag (IVCI/SYADEM)//
  
 François Kaag introduced a method for using NUVA to generate metrics that evaluate the completeness, precision, and redundancy of other vaccine coding systems. These metrics can help developers understand the strengths and limitations of their systems and support better cross-system alignment. François Kaag introduced a method for using NUVA to generate metrics that evaluate the completeness, precision, and redundancy of other vaccine coding systems. These metrics can help developers understand the strengths and limitations of their systems and support better cross-system alignment.
  
-==== Key Points ====+=== Key Points ===
  
   * **Abstract vs. Concrete Vaccines**: François clarified the terminology around **abstract vaccines**—concepts that describe the vaccine type or valence structure without referring to a branded product. Examples:   * **Abstract vs. Concrete Vaccines**: François clarified the terminology around **abstract vaccines**—concepts that describe the vaccine type or valence structure without referring to a branded product. Examples:
Line 497: Line 499:
  
  
-==== Slide decks ====+===== Slide decks =====
 ^ Slides  ^ Presenter  ^ Organization  ^ ^ Slides  ^ Presenter  ^ Organization  ^
 | **TRAINING SESSION**  | | | | **TRAINING SESSION**  | | |
  • ivci/bordeaux_2025.txt
  • Last modified: 2025/05/30 08:47
  • by fkaag